Original Source(s)
Related Content
Extended antiviral therapy may not improve long COVID
Nirmatrelvir–ritonavir for up to 25 days failed to improve cognitive, autonomic, or exercise symptoms compared with placebo in a phase 2 trial.
September 4, 2026
-
4 min
Enterovirus diversity may limit treatment advances
Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.
September 8, 2026
-
4 min